Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine metabolic cardioprotection in inducible myocardial ischemia
2021-001564-26Phase 4Terminated
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of trimetazidine in cardiac ischemia, sponsored by Fondazione Toscana Gabriele Monasterio. Primary endpoint: Quantitative change in ischemic area by regional glucose metabolism. Started Feb 2022; status: terminated.
02
Drugs
trimetazidine
03
Conditions
cardiac ischemia
Beyond the preview
Go deeper on 2021-001564-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001564-26.